HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage
biopharmaceutical company engaged in the discovery and development of
new orally administered treatments for Alzheimer’s disease and diabetes,
among other therapeutic areas, today provided a corporate update and
reported financial and operational results for the first quarter ended
March 31, 2017.

“vTv remains committed to advancing the science behind our innovative
approach to Alzheimer’s disease and type 2 diabetes,” said Steve
Holcombe, president and CEO of vTv Therapeutics. “As we anticipate
completing enrollment of the second and final cohort of our Phase 3
trial during the second quarter, we are hopeful that our unique
hypothesis in targeting the receptor for advanced glycation endproducts
(RAGE) will position us to be the first biopharmaceutical company to
bring an investigational therapy before the FDA that could potentially
slow the progression of Alzheimer's disease.”

First Quarter 2017 Recent Highlights

AD/PD 2017 Panel Participation

AD/PDTM 2017 Alzheimer Clinical Phase 3
Forum: The Race For The First Disease Modifying Drug For AD: Factors For
Success

During the 13th International Conference on Alzheimer’s &
Parkinson’s Diseases vTv’s Chief Medical Officer, Larry Altstiel, MD,
Ph.D., along with other leading industry experts, participated in a
forum discussion on Phase 3 clinical trial design for drugs that slow
the progression of Alzheimer’s disease.

ENDO 2017 Annual Meeting

Phase 2b AGATA Study with TTP399 in Type 2 diabetes

Dr. Adrian Vella of the Mayo Clinic presented results from the phase 2
AGATA study of vTv Therapeutics’ glucokinase activator (GKA) TTP399,
in which the 800 mg dose demonstrated a reduction in HbA1C as well as
a trend in weight loss for adults with type 2 diabetes.

Upcoming Anticipated Milestones

STEADFAST Study (azeliragon in Alzheimer’s disease): Expected to
complete enrollment in Part B of Phase 3 study during the second quarter
of 2017.

First Quarter 2017 Financial Results

Cash Position: Cash and cash equivalents as of March 31, 2017
were $45.2 million compared to $51.5 million as of December 31, 2016.
vTv expects that its cash and cash equivalents will be sufficient to
fund its operations through the receipt of top-line results for Part A
of our STEADFAST Study which are expected in March 2018.

R&D Expenses: Research and development expenses were $11.0
million in the first quarter of 2017, compared to $11.1 million in the
fourth quarter of 2016. The decrease in research and development
expense was primarily driven by decreases in spending for the Phase 2
LOGRA study which completed in December 2016 offset by increases in
personnel costs and non-cash compensation expense.

G&A Expenses: General and administrative expenses were $2.8
million in the first quarter of 2017, compared to $2.3 million in the
fourth quarter of 2016. The increase in general and administrative
expenses for the quarter was primarily due to increases in personnel
costs, non-cash compensation expense and professional service expenses.

Net Loss: Net loss was $14.3 million for the first quarter of
2017 compared to net loss of $13.7 million for the fourth quarter of
2016.

Net loss per share of vTv Therapeutics Inc. Class A Common Stock,
basic and diluted

$

(0.44

)

$

(0.42

)

Weighted-average number of vTv Therapeutics Inc. Class A Common
Stock, basic and diluted

9,693,254

9,693,254

vTv Therapeutics, Inc.

Condensed Combined Consolidated Statements of Operations -
Unaudited

(in thousands, except per share data)

Three Months Ended March 31,

2017

2016

Revenue

$

30

$

376

Operating expenses:

Research and development

10,960

11,335

General and administrative

2,824

2,581

Total operating expenses

13,784

13,916

Operating loss

(13,754

)

(13,540

)

Interest income

27

23

Interest expense

(559

)

(2

)

Other income (loss), net

—

(1

)

Loss before income taxes and noncontrolling interest

(14,286

)

(13,520

)

Income tax provision

—

—

Net loss before noncontrolling interest

(14,286

)

(13,520

)

Less: net loss attributable to noncontrolling interest

(10,066

)

(9,668

)

Net loss attributable to vTv Therapeutics Inc.

$

(4,220

)

$

(3,852

)

Net loss per share of vTv Therapeutics Inc. Class A Common Stock,
basic and diluted

$

(0.44

)

$

(0.42

)

Weighted-average number of vTv Therapeutics Inc. Class A Common
Stock, basic and diluted

9,693,254

9,229,645

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer’s disease and Type 2 diabetes as well as
treatment of inflammatory disorders and the prevention of muscle
weakness.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks
and uncertainties. These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading “Risk Factors” in
our Annual Report on Form 10-K and our other filings with the SEC. These
forward-looking statements reflect our views with respect to future
events as of the date of this release and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties, you
should not place undue reliance on these forward-looking statements.
These forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law, we
undertake no obligation to update or review publicly any forward-looking
statements, whether as a result of new information, future events or
otherwise after the date of this release. We anticipate that subsequent
events and developments will cause our views to change. Our
forward-looking statements do not reflect the potential impact of any
future acquisitions, merger, dispositions, joint ventures or investments
we may undertake. We qualify all of our forward-looking statements by
these cautionary statements.